Cardarine (GW-501516): Research Summary and Risk Assessment

Most research compounds used off-label are banned by sports authorities but otherwise unregulated. GW-501516 (Cardarine) is different: its clinical development was permanently terminated in 2007 after rodent studies showed rapid cancer proliferation at doses previously considered therapeutic, yet it remains widely available through underground suppliers and frequently misrepresented as a "SARM" in online communities.

The Peroxisome Proliferator-Activated Receptor Delta Agonist Behind the Name

GW-501516, commonly known as Cardarine, is a synthetic small-molecule agonist of peroxisome proliferator-activated receptor delta (PPARδ). It was developed in the 1990s through a collaboration between GlaxoSmithKline and Ligand Pharmaceuticals as a potential treatment for metabolic and cardiovascular diseases.

The compound belongs to the PPAR family of nuclear receptor proteins, which regulate gene transcription related to lipid metabolism, glucose homeostasis, and inflammation. Unlike steroids or actual selective androgen receptor modulators (SARMs), GW-501516 does not bind androgen receptors and exerts no direct androgenic effects. The common categorization as a SARM appears to stem from its popularity in similar online communities and its use alongside anabolic compounds, not from its pharmacological mechanism.

The molecular structure—a thiazole and phenoxyacetic acid derivative—was optimized for potent and selective PPARδ activation with minimal activity at related PPARα and PPARγ receptors. Initial preclinical work demonstrated dramatic metabolic effects in rodents, leading to Phase I and Phase II human trials for dyslipidemia and metabolic syndrome. All clinical development ceased abruptly in 2007 when long-term rodent carcinogenicity studies revealed dose-dependent tumor formation across multiple organ systems.

How PPARδ Activation Shifts Cellular Fuel Preference and Oxidative Capacity

PPARδ functions as a ligand-activated transcription factor. When GW-501516 binds the receptor, the PPARδ-retinoid X receptor (RXR) heterodimer undergoes conformational changes that recruit coactivator proteins and bind to peroxisome proliferator response elements (PPREs) in gene promoters. This cascade upregulates genes involved in fatty acid oxidation, mitochondrial biogenesis, and slow-twitch muscle fiber development.

The downstream metabolic shift is observable within hours in cell culture and within days in animal models. Key target genes include:

• CPT1 and ACOX1: Enzymes that facilitate fatty acid transport into mitochondria and peroxisomal β-oxidation
• PDK4: Pyruvate dehydrogenase kinase 4, which inhibits glucose oxidation and forces cellular reliance on fat as fuel
• UCP2 and UCP3: Uncoupling proteins that increase thermogenesis and metabolic rate
• PGC-1α: A master regulator of mitochondrial biogenesis and oxidative metabolism

In skeletal muscle, PPARδ activation shifts fiber-type composition. Rodent studies show increased expression of type I (slow-twitch, oxidative) muscle fiber markers and enhanced mitochondrial density. This effect appears more pronounced in glycolytic muscle groups, suggesting GW-501516 can partially reprogram metabolic phenotype.

The compound also affects glucose metabolism indirectly. By forcing cells toward fatty acid oxidation, it reduces reliance on glucose and improves insulin sensitivity in models of metabolic dysfunction. Adipose tissue studies show enhanced lipolysis and reduced triglyceride accumulation. These mechanisms explain the lipid-lowering and insulin-sensitizing effects observed in early human trials.

Promising Metabolic Data Followed by Tumor Proliferation Across Multiple Organ Systems

The preclinical efficacy data in rodents was striking. In genetically obese and diabetic mouse models, GW-501516 administration reduced body weight, lowered fasting glucose, improved lipid profiles, and increased exercise endurance by 50-70% compared to controls. Studies using treadmill running to exhaustion showed treated mice could run nearly twice as long as untreated animals, an effect observed even without training.

In 2006-2007, GlaxoSmithKline conducted Phase II clinical trials in patients with dyslipidemia. The published results showed dose-dependent increases in HDL cholesterol (up to 17% increase at 10 mg/day) and reductions in triglycerides (approximately 30% reduction at higher doses) over 12 weeks. The compound was well-tolerated in these short-term studies with no serious adverse events reported at therapeutic doses (2.5-10 mg/day).

What ended development was data from long-term rodent carcinogenicity studies mandated for regulatory approval. Rats and mice treated with GW-501516 for 104 weeks developed malignant tumors at multiple organ sites, including the liver, bladder, stomach, tongue, skin, and thyroid. Tumor incidence increased with both dose and duration. Critically, tumors appeared at doses that were considered therapeutic (in some studies as low as 3 mg/kg/day in rats—roughly equivalent to human doses being explored clinically when allometrically scaled).

The cancer mechanism is not definitively established but likely relates to PPARδ's role in cell proliferation and survival. PPARδ activation has been shown in numerous cancer cell lines to promote survival, inhibit apoptosis, and enhance angiogenesis. The transcriptional program that improves oxidative metabolism in healthy tissue may provide survival advantages to initiated cancer cells. A 2009 study published in Cancer Prevention Research demonstrated that GW-501516 accelerated tumor growth in multiple mouse models of carcinogenesis, prompting an editorial warning from the American Association for Cancer Research.

No long-term human safety data exists. The longest human exposure in published trials was approximately 12 weeks. There are no published human trials assessing cancer risk with chronic exposure.

Research Dosing Parameters from the Discontinued Clinical Program

All published human data comes from the terminated clinical trials conducted between 2004-2007. In these studies:

• Therapeutic dose range: 2.5 mg to 10 mg once daily, taken orally
• Study duration: Up to 12 weeks
• Half-life: Approximately 16-24 hours based on Phase I pharmacokinetic data
• Bioavailability: Oral administration showed consistent absorption; no published data on injectable formulations

Rodent studies typically used doses ranging from 0.5 mg/kg to 10 mg/kg daily. The cancer studies showed tumor formation at doses as low as 3 mg/kg/day in rats over two years—a dose roughly equivalent to 0.5 mg/kg in humans when adjusted for body surface area. This corresponds to approximately 35 mg for a 70 kg human, though such direct cross-species extrapolations carry significant uncertainty.

Underground sources typically recommend 10-20 mg daily, often split into two doses, despite no published human data supporting safety at these levels or durations beyond a few weeks. This dosing has no grounding in peer-reviewed literature and exists purely in online forums.

The compound is lipophilic with good metabolic stability. No significant drug interactions were identified in Phase I studies, though as a nuclear receptor modulator, interaction with other PPARδ ligands or metabolic drugs is plausible. The elimination route is primarily hepatic.

GW-501516 is intended for research purposes only and is not approved for human consumption in any jurisdiction.

Frequently Asked Questions

Q: Is GW-501516 a SARM?

No. Despite being sold alongside SARMs in the same online markets, GW-501516 does not interact with androgen receptors and has no androgenic mechanism. It is a PPARδ agonist that affects metabolism, not muscle protein synthesis directly. The misclassification appears to be marketing-driven rather than pharmacologically accurate.

Q: Was the cancer risk only seen at high doses in rodents?

No. Tumor formation was observed across the entire tested dose range in long-term rodent studies, including doses that were initially considered therapeutic. Some studies showed increased cancer incidence at doses as low as 3 mg/kg/day in rats—roughly equivalent on a body surface area basis to doses that were being tested in human clinical trials. The compound was not shown to be safe at any chronic dose in animals.

Q: How long does GW-501516 stay in your system?

The terminal half-life is approximately 16-24 hours based on Phase I human pharmacokinetic data. However, detection methods for anti-doping purposes can identify metabolites for much longer. The World Anti-Doping Agency (WADA) has reported detection of GW-501516 metabolites in urine samples for weeks after administration, and some testing protocols claim detection windows extending months.

Q: Are there any legitimate ongoing human studies of GW-501516?

No active clinical trials are registered as of 2024. All human studies were terminated in 2007 following the rodent cancer findings, and no pharmaceutical sponsor has attempted to revive development. Any current human use occurs outside regulatory oversight, without safety monitoring, and with no established risk management protocols.

Q: Does GW-501516 improve endurance without exercise?

In rodent studies, yes—sedentary mice treated with GW-501516 showed improved treadmill running time without training. However, the effect was significantly greater in trained animals, suggesting the compound amplifies training adaptations rather than replacing them. No controlled human studies of exercise performance have been published, so the magnitude of any endurance benefit in humans remains speculative.

---

This summary reflects published research data and is not medical advice. GW-501516 is not approved for human use, carries demonstrated cancer risk in animal models, and has no established human safety profile for chronic use. Anyone considering use assumes substantial and unknown long-term health risks.